1. Apply information from basic, preclinical studies of mTOR Complex 2 as a clinically relevant target for HER2+ and basal-like/triple-negative breast cancer (TNBC) to understanding the complex role mTOR plays in breast tumorigenesis and progression.

2. List advantages and challenges involved with targeting mTORC2 using nanoparticle-delivered siRNA.

WebEx Info:

Event address for attendees: https://uwmadison.webex.com/uwmadison/onstage/g.php?MTID=e42a5f08a71c142e371b8e8754774dc01

Session date: 
02/10/2021 - 8:00am to 9:00am CST
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.
Discloser List CME Internal Report
Dr. Dana Brantley-Sieders